Financial Comparison: Pulmonx (NASDAQ:LUNG) vs. Assure (NASDAQ:IONM)

Pulmonx (NASDAQ:LUNG) and Assure (NASDAQ:IONM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility and Risk

Pulmonx has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Assure has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Institutional & Insider Ownership

88.1% of Pulmonx shares are owned by institutional investors. Comparatively, 21.8% of Assure shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 28.1% of Assure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pulmonx and Assure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1	1	5	0	2.57
Assure	0	0	1	0	3.00

Pulmonx presently has a consensus target price of $15.00, suggesting a potential upside of 47.49%. Assure has a consensus target price of $25.33, suggesting a potential upside of 9,145.74%. Given Assure’s stronger consensus rating and higher possible upside, analysts plainly believe Assure is more favorable than Pulmonx.

Earnings and Valuation

This table compares Pulmonx and Assure’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$53.66 million	7.21	-$58.92 million	($1.61)	-6.32
Assure	$9.73 million	0.15	-$30.11 million	N/A	N/A

Assure has lower revenue, but higher earnings than Pulmonx.

Profitability

This table compares Pulmonx and Assure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-99.76%	-40.65%	-30.63%
Assure	N/A	-379.76%	-118.95%

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

About Assure

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.